semaglutide oral cardiovascular indication 2025 news outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice EASD 2025: Pooled analysis highlights

It can reduce the risk of serious cardiovascular complications in individuals with type 2 diabetes and heart disease

GLP-1 medications like Ozempic and Mounjaro (which have been approved for treating type 2 diabetes but are sometimes used off-label for weight loss), as well as Wegovy and Zepbound (which have been approved to treat overweight and obesity), have soared in popularity due to their effectiveness as weight loss aids

Some patients report headaches , particularly in the early treatment phase

You have severe or worsening digestive symptoms

its about creating a body that works better, feels stronger, and maintains the metabolic health needed for long-term success